The subsequent development of immuno-oncology with the introduction of antibodies against PD-1 (nivolumab, pembrolizumab), PD-L1 (atezolizumab, durvalumab, and avelumab), and CTLA4 (ipilimumab) has led to a paradigm shift in the treatment of cancer (5). Here, PDCD1 is linked to cancer.